skip to Global Navigation Bar skip to main content

homeHome > About Us > Recruitment > News


News Content
Daewoong Pharmaceutical initiates development of new medication for hearing impairment (First in Class) with Yonsei University based on the ion channel platform technology.
Date 2019-06-13 Hit 1568
News List
Prev Daewoong Pharmaceutical’s diabetes treatment, ‘DWP16001,’ approved for clinical test phase 2 in Korea.
Next DWN12088, Daewoong Pharmaceutical’s new drug for pulmonary fibrosis, enters global clinical studies phase 1.